Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Bradley Patton Dixon

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS
Phone720/777-3718

    Collapse Research 
    Collapse research activities and funding
    K08DK081737     (DIXON, BRADLEY P)Jul 1, 2011 - Oct 31, 2015
    NIH
    DNA Damage and Response in the Bladder Microenvironment.
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dixon BP, Greenbaum LA, Huang L, Rajan S, Ke C, Zhang Y, Li L. Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney Int Rep. 2023 Nov; 8(11):2284-2293. PMID: 38025230.
      View in: PubMed
    2. Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 09; 12(9):e230036. PMID: 37515502.
      View in: PubMed
    3. Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment." Kidney Int. 2021;100:225-237. Kidney Int. 2023 Jul; 104(1):205. PMID: 37349053.
      View in: PubMed
    4. Stenson EK, Edelstein CL, You Z, Miyazaki-Anzai S, Thurman JM, Dixon BP, Zappitelli M, Goldstein SL, Akcan Arikan A, Kendrick J. Urine Complement Factor Ba Is Associated with AKI in Critically Ill Children. Kidney360. 2023 03 01; 4(3):326-332. PMID: 36758197.
      View in: PubMed
    5. Nester C, Appel GB, Bomback AS, Bouman KP, Cook HT, Daina E, Dixon BP, Rice K, Najafian N, Hui J, Podos SD, Langman CB, Lightstone L, Parikh SV, Pickering MC, Sperati CJ, Trachtman H, Tumlin J, de Vries AP, Wetzels JFM, Remuzzi G. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. Am J Nephrol. 2022; 53(10):687-700. PMID: 36423588.
      View in: PubMed
    6. Podos SD, Trachtman H, Appel GB, Bomback AS, Dixon BP, Wetzels JFM, Cook HT, Parikh SV, Pickering MC, Tumlin J, Langman CB, Lightstone L, Sperati CJ, Daina E, Bouman KP, Rice K, Thanassi JA, Huang M, Nester C, Remuzzi G. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. Am J Nephrol. 2022; 53(10):675-686. PMID: 36404708.
      View in: PubMed
    7. Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, Mazo A, Goilav B, Boneparth A, Kallash M, Zeid A, Seeherunvong W, Scobell RR, Alhamoud I, Carter CE, Shah S, Straatmann CE, Dixon BP, Cooper JC, Nelson RD, Levy DM, Brunner HI, Verghese PS, Wenderfer SE. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol. 2023 05; 38(5):1653-1665. PMID: 36251074.
      View in: PubMed
    8. Stenson EK, Kendrick J, Dixon B, Thurman JM. The complement system in pediatric acute kidney injury. Pediatr Nephrol. 2023 05; 38(5):1411-1425. PMID: 36203104.
      View in: PubMed
    9. Chan M, Hanna MG, Willard N, Treece A, Dixon BP. Hypocomplementemic Atypical IgA Vasculitis: A Case Report. Front Pediatr. 2022; 10:886371. PMID: 35757129.
      View in: PubMed
    10. Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther. 2022 Jul; 47(7):1081-1087. PMID: 35304755.
      View in: PubMed
    11. Benoit SW, Fukuda T, VandenHeuvel K, Witte D, Fuller C, Willis J, Dixon BP, Drake KA. Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing. Front Pediatr. 2022; 10:841051. PMID: 35281224.
      View in: PubMed
    12. Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA. Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes. Clin J Am Soc Nephrol. 2022 01; 17(1):65-74. PMID: 34732529.
      View in: PubMed
    13. Stenson EK, You Z, Reeder R, Norris J, Scott HF, Dixon BP, Thurman JM, Frazer-Abel A, Mourani P, Kendrick J. Complement Activation Fragments Are Increased in Critically Ill Pediatric Patients with Severe AKI. Kidney360. 2021 12 30; 2(12):1884-1891. PMID: 35419539.
      View in: PubMed
    14. Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237. PMID: 33307104.
      View in: PubMed
    15. Marchbank KJ, Frazer-Abel A, Dragon-Durey MA, Dixon BP. Editorial: Autoantibodies in Kidney Diseases. Front Immunol. 2020; 11:591338. PMID: 33042166.
      View in: PubMed
    16. Shin HS, Nester CM, Dixon BP. Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients. Clin Nephrol Case Stud. 2019; 7:35-40. PMID: 31312592.
      View in: PubMed
    17. Hopley C, Andrews E, Klem P, Jonjak M, Grothe A, Ten Eyck P, You Z, Billups SJ, Lyon C, Kennelty K, Dixon B, Jalal D. Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD. Pilot Feasibility Stud. 2019; 5:23. PMID: 30805198.
      View in: PubMed
    18. Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2019 02; 66(1):235-246. PMID: 30454746.
      View in: PubMed
    19. Benoit SW, Dixon BP, Goldstein SL, Bennett MR, Lane A, Lounder DT, Rotz SJ, Gloude NJ, Lake KE, Litts B, Davies SM. A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 09; 54(9):1453-1461. PMID: 30700793.
      View in: PubMed
    20. Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2018 06; 65(3):509-525. PMID: 29803280.
      View in: PubMed
    21. Fraga-Rodriguez GM, Bri?-Sanagustin S, Tur?n-Vi?as E, Dixon BP, Carreras-Gonz?lez E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep. 2017 Apr 26; 2017. PMID: 28446488.
      View in: PubMed
    22. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19; 122(12):2003-7. PMID: 23814021.
      View in: PubMed
    23. Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell cycle control and DNA damage response of conditionally immortalized urothelial cells. PLoS One. 2011 Jan 28; 6(1):e16595. PMID: 21305048.
      View in: PubMed
    24. Dixon BP, Lu L, Chu A, Bissler JJ. RecQ and RecG helicases have distinct roles in maintaining the stability of polypurine.polypyrimidine sequences. Mutat Res. 2008 Aug 25; 643(1-2):20-8. PMID: 18582477.
      View in: PubMed
    Dixon's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (99) concept(s)
    _
    Co-Authors Expand Description
    See all (14) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)